GMP certification for Exothera further extends its viral vector manufacturing capacity
The expansion makes Exothera one of the largest viral vector facilities in Europe
The expansion makes Exothera one of the largest viral vector facilities in Europe
The facility will manufacture its Herceptin biosimilar, Tuznue
The GMP certificate is valid for three years until April 2024.
FY26 revenue rises to Rs. 4,359 crore as India’s leading CDMO strengthens global footprint with EU GMP certifications, UK MHRA approval and Europe supplies
The certification follows an inspection conducted by the Malta Medicines Authority between January 29, 2026, and February 3, 2026
The company highlighted a series of strategic moves during the year, including the acquisition of WOKADINE, marking its entry into the Rs. 648 Cr Povidone Iodine market
Successful inspection outcome strengthens company’s regulatory compliance and manufacturing standards in China
Operational leverage kicked in during the quarter, with adjusted EBITDA rising 21% year-on-year to Rs 147 crore
Subscribe To Our Newsletter & Stay Updated